Strong Ending Cash Balance of $9.3M LAVAL, QC, Aug. 12, 2020/CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (`Crescita` or the `Company`), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (`R&D`) and manufacturing capabilities, today reported its financial results for the second quarter ended June 30, 2020(`Q2-F2020`). All amounts in this press release are in thousands of Canadian dollars (`CAD`) unless otherwise noted. Financial Highlights - Q2-F2020 vs. Q2-F2019 Revenue was $1,733, a decrease of $7,629. In Q2-F2019, the Company recognized $5,459in up-front payments and guaranteed future minimum royalties...
|
